Filtered By:
Management: Marketing
This page shows you your search results in order of relevance. This is page number 9.
Order by Relevance | Date
Total 200 results found since Jan 2013.
NUEDEXTA(R) Effective for Pseudobulbar Affect (PBA) in Patients with Alzheimer's Disease and other Dementias, Stroke and Traumatic Brain Injury
PRISM II study published in BMC Neurology adds to clinical evidence demonstrating NUEDEXTA efficacy for PBA across diverse neurological disorders
ALISO VIEJO, Calif., June 8, 2016 -- (Healthcare Sales & Marketing Network) -- Avanir Pharmaceuticals, Inc... Biopharmaceuticals, NeurologyAvanir Pharmaceuticals, Otsuka, NUEDEXTA, pseudobulbar affect
Source: HSMN NewsFeed - June 9, 2016 Category: Pharmaceuticals Source Type: news
Prasugrel Use in Real Life: A Report From the Outpatient Setting in France
The objective of this study was to provide descriptive statistics on patterns of prasugrel usage in the outpatient setting in France. This retrospective study was conducted to describe treatment patterns for prasugrel in the outpatient setting in France using the Intercontinental Marketing Services (IMS) Disease Analyzer database, which collates electronic medical records updated by a nationally representative database of 1200 French general practitioners (GPs). Anonymous data were collected prospectively at each follow‐up visit. The study population consisted of patients with ≥1 prescription for prasugrel in the outpa...
Source: Clinical Cardiology - April 30, 2016 Category: Cardiology Authors: Pierre Sabouret, Magali Taiel‐Sartral, Florence Chartier, Sabine Akiki, Thomas Cuisset Tags: Quality and Outcomes Source Type: research
Coconut Oil: Why You Should Question the Hype
by Carra Richling
Coconut has become a popular and trendy "super food." Ever since some preliminary research started claiming that it can cure everything from heart disease to Alzheimer's, and even aid in weight loss, coconut products have flooded the market. They include coconut oils, margarines, milks, yogurts and ice cream, and many products are substituting in coconut oil in order to gain market value.
There is, however, still a dearth of validated scientific research on the benefits of coconut, so it remains unclear whether or not the trend is the result of marketing hype. For example, the Alzheimer's Association no...
Source: Healthy Living - The Huffington Post - June 22, 2016 Category: Consumer Health News Source Type: news
No more sneaking sugar into packaged foods
The iconic black-and-white Nutrition Facts label you find on packaged foods in the United States is getting its first makeover in two decades. The federal government decided last month to update the food label beginning in 2018 by listing how much sugar has been added to a product.
The current label lumps added sugar with naturally occurring sugars in the foods themselves, which is a deceptive practice, said Dr. John Swartzberg, a UC Berkeley clinical professor emeritus and editorial board chair of the UC Berkeley Wellness Letter. So listing added sugar “will hopefully guide people away from consuming products with a ...
Source: UCLA Newsroom: Health Sciences - June 30, 2016 Category: Universities & Medical Training Source Type: news
The Economic Benefits Of Healthier Eating: Why Corporations Can Be Natural Allies To Promote Better Diets
Nutrition is at the heart of many of the most important issues in our lives. From nourished children to vibrant aging, from social justice to sustainability, how we eat plays a major role in our health, our culture, and our happiness.
Yet, we rarely consider the tremendous economic impact of our food choices. Suboptimal nutrition is the leading cause of poor health in the United States and globally, principally related to chronic diseases such as heart disease, stroke, obesity, diabetes, and several cancers. In many nations, the costs of healthcare dwarf other programs in the national budget. In the United States, nearly ...
Source: Healthy Living - The Huffington Post - July 1, 2016 Category: Consumer Health News Source Type: news
Why 5,000 People Are Suing Over Plavix
Legal action is apparently moving forward involving lawsuits filed by thousands of people who say they suffered serious injuries by taking the once-heralded blood-thinning drug Plavix.
The California Supreme Court ruled late last month that eight product liability lawsuits against Plavix manufacturer Bristol-Myers Squibb and Plavix distributor McKesson Corporation can proceed in San Francisco Superior Court.
Those eight cases involved 678 plaintiffs. They may soon be joined by a multitude of other cases, involving about 5,000 plaintiffs, that have been filed around the country.
There is no word yet on whether Bristol-My...
Source: Healthy Living - The Huffington Post - September 13, 2016 Category: Consumer Health News Source Type: news
Betrixaban - the next direct factor Xa inhibitor?
Authors: Thoenes M, Minguet J, Bramlage K, Bramlage P, Ferrero C
Abstract
INTRODUCTION: Venous thromboembolism is a major global health burden. Since the 1930s, prevention of stroke and pulmonary embolism in these patients has been achieved using conventional anticoagulants, such as heparin and warfarin. However, in recent years, four direct non-vitamin K antagonist oral anticoagulants (DOACs) have entered the market as alternative treatment options. Betrixaban is a fifth DOAC looking to gain marketing approval in the near future, and may have several potentially beneficial properties. Areas covered: Here, we outli...
Source: Expert Review of Hematology - November 6, 2016 Category: Hematology Tags: Expert Rev Hematol Source Type: research
Expensive New Diabetes Drugs Add Nothing But Cost And Complications
This is the fourth in an ongoing series of blogs exposing the rampant misuse of the medications so aggressively promoted by greedy drug companies.
I am very lucky in having the perfect partner in this truth-vs-power effort to contradict Pharma propaganda with evidence based fact.
Dick Bijl is President of the International Society of Drug Bulletins (ISDB), an impressive association of 53 national drug bulletins from all around the world, each of which publishes the best available data on the pluses and minuses of different medications.
Drug bulletins help patients and doctors see through the misleading misinformation ge...
Source: Science - The Huffington Post - November 17, 2016 Category: Science Source Type: news
Stop marketing our kids to death with ads for foods and drinks, Heart and Stroke urges
Canadian kids and teens are bombarded by advertising for food and beverages in movies, video games, apps and social media — and that needs to stop, according to a new report.
Source: CBC | Health - February 1, 2017 Category: Consumer Health News Tags: News/Health Source Type: news
EMA Recommends EU Marketing of Edoxaban in Atrial Fibrillation EMA Recommends EU Marketing of Edoxaban in Atrial Fibrillation
The recommendation is for prevention of stroke and systemic embolism in atrial fibrillation and for the treatment and prevention of DVT and PE.International Approvals
Source: Medscape Medical News Headlines - February 24, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news
New Study Shows Prevencios Simple Blood Test Determines Risk of Heart Attack, Stroke, or Cardiovascular Death
KIRKLAND, Wash.--(Healthcare Sales & Marketing Network)--Prevencio, Inc. today announces the presentation of data which demonstrate that a simple blood test is more accurate than commonly-used risk factors in determining whether a person will have a heart ... Diagnostics, Cardiology Prevencio, HART CVE, HART CAD
Source: HSMN NewsFeed - March 17, 2017 Category: Pharmaceuticals Source Type: news
‘Forever Young’†—Testosterone replacement therapy: a blockbuster drug despite flabby evidence and broken promises
<span class="paragraphSection"><div class="boxTitle">Abstract</div>In the last decade, testosterone replacement therapy (TRT) has been increasingly prescribed to treat a controversial condition known as ‘late-onset hypogonadism (LOH)’. This syndrome is diagnosed in men who, for no discernible reason other than older age, obesity or ill health have serum testosterone concentrations below the normal range for healthy young men and report one or more of the following symptoms: muscle weakness or wasting, mood, behaviour and cognition-related symptoms and sexual function or libido impairment. However, rec...
Source: Human Reproduction - February 22, 2017 Category: Reproduction Medicine Source Type: research
CytoSorbents touts Refresh trial study data
CytoSorbents (OTC:CTSO) today presented results from the Refresh trial of its CytoSorb blood purification technology, touting that the trial met its safety goals and that treatment reduced toxic inflammatory mediators during complex heart surgery.
Data was presented at the American Association for Thoracic Surgery’s centennial conference in Boston this week.
The Monmouth Junction, N.J.-based company’s CytoSorb is an extracorporeal cytokine filter, made up of biocompatible, porous polymer beads that use pore capture and surface adsorption to remove toxic substances from the blood and other bodily fluids.
The pr...
Source: Mass Device - May 5, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Blood Management Clinical Trials CytoSorbents Corp. Source Type: news
Ex-Invacare chief Mixon pulls the trigger on convertible shares
Invacare (NYSE:IVC) said yesterday that the former chairman & CEO who rescued the company from the doldrums in the 1980s, Malachi Mixon III, is pulling the trigger on the more than 700,000 convertible shares he controls.
The 1-for-1 exchange will take Invacare’s voting power from 40,155,366 votes to 33,820,158 votes, the Elyria, Ohio-based company said.
“The conversion will substantially diminish the significance of the company’s dual class voting structure, as after completion, the holders of the common shares will represent approximately 99.5% of the company’s total outstanding voting power,...
Source: Mass Device - June 1, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Wall Street Beat Invacare Rehabilitation Equipment Source Type: news
Zynex Hires Chief Financial Officer
LONE TREE, Colo., June 9, 2017 -- (Healthcare Sales & Marketing Network) -- Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilita... Devices, Neurology, Personnel Zynex, electrotherapy
Source: HSMN NewsFeed - June 9, 2017 Category: Pharmaceuticals Source Type: news
